146 related articles for article (PubMed ID: 26961119)
1. Immunological and angiogenic markers during metronomic temozolomide and cyclophosphamide in canine cancer patients.
Denies S; Cicchelero L; de Rooster H; Daminet S; Polis I; Van de Maele I; Sanders NN
Vet Comp Oncol; 2017 Jun; 15(2):594-605. PubMed ID: 26961119
[TBL] [Abstract][Full Text] [Related]
2. Immunological, anti-angiogenic and clinical effects of intratumoral interleukin 12 electrogene therapy combined with metronomic cyclophosphamide in dogs with spontaneous cancer: A pilot study.
Cicchelero L; Denies S; Vanderperren K; Stock E; Van Brantegem L; de Rooster H; Sanders NN
Cancer Lett; 2017 Aug; 400():205-218. PubMed ID: 27693635
[TBL] [Abstract][Full Text] [Related]
3. Phase I lead-in and subsequent randomized trial assessing safety and modulation of regulatory T cell numbers following a maximally tolerated dose doxorubicin and metronomic dose cyclophosphamide combination chemotherapy protocol in tumour-bearing dogs.
Rasmussen RM; Kurzman ID; Biller BJ; Guth A; Vail DM
Vet Comp Oncol; 2017 Jun; 15(2):421-430. PubMed ID: 26522053
[TBL] [Abstract][Full Text] [Related]
4. Clinical and immunomodulatory effects of toceranib combined with low-dose cyclophosphamide in dogs with cancer.
Mitchell L; Thamm DH; Biller BJ
J Vet Intern Med; 2012; 26(2):355-62. PubMed ID: 22303814
[TBL] [Abstract][Full Text] [Related]
5. Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model.
Banissi C; Ghiringhelli F; Chen L; Carpentier AF
Cancer Immunol Immunother; 2009 Oct; 58(10):1627-34. PubMed ID: 19221744
[TBL] [Abstract][Full Text] [Related]
6. Toxicity of metronomic cyclophosphamide chemotherapy in a UK population of cancer-bearing dogs: a retrospective study.
Harper A; Blackwood L
J Small Anim Pract; 2017 Apr; 58(4):227-230. PubMed ID: 28133740
[TBL] [Abstract][Full Text] [Related]
7. Circulating thrombospondin 1 level as a surrogate marker in patients receiving cyclophosphamide-based metronomic chemotherapy.
Lansiaux A; Salingue S; Dewitte A; Clisant S; Penel N
Invest New Drugs; 2012 Feb; 30(1):403-4. PubMed ID: 20449626
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of toxicities from combined metronomic and maximal-tolerated dose chemotherapy in dogs with osteosarcoma.
Bracha S; Walshaw R; Danton T; Holland S; Ruaux C; Obradovich J
J Small Anim Pract; 2014 Jul; 55(7):369-74. PubMed ID: 24803081
[TBL] [Abstract][Full Text] [Related]
9. Association between baseline VEGF/sVEGFR-2 and VEGF/TSP-1 ratios and response to metronomic chemotherapy using cyclophosphamide and celecoxib in patients with advanced breast cancer.
Perroud HA; Rico MJ; Alasino CM; Pezzotto SM; Rozados VR; Scharovsky OG
Indian J Cancer; 2013; 50(2):115-21. PubMed ID: 23979202
[TBL] [Abstract][Full Text] [Related]
10. Incidence of sterile hemorrhagic cystitis in tumor-bearing dogs concurrently treated with oral metronomic cyclophosphamide chemotherapy and furosemide: 55 cases (2009-2015).
Chan CM; Frimberger AE; Moore AS
J Am Vet Med Assoc; 2016 Dec; 249(12):1408-1414. PubMed ID: 27901449
[TBL] [Abstract][Full Text] [Related]
11. EGFR amplified and overexpressing glioblastomas and association with better response to adjuvant metronomic temozolomide.
Cominelli M; Grisanti S; Mazzoleni S; Branca C; Buttolo L; Furlan D; Liserre B; Bonetti MF; Medicina D; Pellegrini V; Buglione M; Liserre R; Pellegatta S; Finocchiaro G; Dalerba P; Facchetti F; Pizzi M; Galli R; Poliani PL
J Natl Cancer Inst; 2015 May; 107(5):. PubMed ID: 25739547
[TBL] [Abstract][Full Text] [Related]
12. Glutathione-S-transferase-theta genotypes and the risk of cyclophosphamide toxicity in dogs.
Ekena J; Wood E; Manchester A; Chun R; Trepanier LA
Vet Comp Oncol; 2018 Dec; 16(4):529-534. PubMed ID: 29984447
[TBL] [Abstract][Full Text] [Related]
13. Retrospective comparison of three doses of metronomic chlorambucil for tolerability and efficacy in dogs with spontaneous cancer.
Custead MR; Weng HY; Childress MO
Vet Comp Oncol; 2017 Sep; 15(3):808-819. PubMed ID: 27136377
[TBL] [Abstract][Full Text] [Related]
14. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients.
Ghiringhelli F; Menard C; Puig PE; Ladoire S; Roux S; Martin F; Solary E; Le Cesne A; Zitvogel L; Chauffert B
Cancer Immunol Immunother; 2007 May; 56(5):641-8. PubMed ID: 16960692
[TBL] [Abstract][Full Text] [Related]
15. Prospective trial of metronomic chlorambucil chemotherapy in dogs with naturally occurring cancer.
Leach TN; Childress MO; Greene SN; Mohamed AS; Moore GE; Schrempp DR; Lahrman SR; Knapp DW
Vet Comp Oncol; 2012 Jun; 10(2):102-12. PubMed ID: 22236329
[TBL] [Abstract][Full Text] [Related]
16. Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome.
Ge Y; Domschke C; Stoiber N; Schott S; Heil J; Rom J; Blumenstein M; Thum J; Sohn C; Schneeweiss A; Beckhove P; Schuetz F
Cancer Immunol Immunother; 2012 Mar; 61(3):353-62. PubMed ID: 21915801
[TBL] [Abstract][Full Text] [Related]
17. Metronomic cyclophosphamide induces regulatory T cells depletion and PSA-specific T cells reactivation in patients with biochemical recurrent prostate cancer.
Laheurte C; Thiery-Vuillemin A; Calcagno F; Legros A; Simonin H; Boullerot L; Jacquin M; Nguyen T; Mouillet G; Borg C; Adotévi O
Int J Cancer; 2020 Aug; 147(4):1199-1205. PubMed ID: 31749145
[TBL] [Abstract][Full Text] [Related]
18. Furosemide for prevention of cyclophosphamide-associated sterile haemorrhagic cystitis in dogs receiving metronomic low-dose oral cyclophosphamide.
Setyo L; Ma M; Bunn T; Wyatt K; Wang P
Vet Comp Oncol; 2017 Dec; 15(4):1468-1478. PubMed ID: 28194917
[TBL] [Abstract][Full Text] [Related]
19. Effective treatment of advanced human melanoma metastasis in immunodeficient mice using combination metronomic chemotherapy regimens.
Cruz-Munoz W; Man S; Kerbel RS
Clin Cancer Res; 2009 Aug; 15(15):4867-74. PubMed ID: 19622578
[TBL] [Abstract][Full Text] [Related]
20. Cyclophosphamide-based metronomic chemotherapy: after 10 years of experience, where do we stand and where are we going?
Penel N; Adenis A; Bocci G
Crit Rev Oncol Hematol; 2012 Apr; 82(1):40-50. PubMed ID: 21641231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
